SITE001-0119

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2022-07-22

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-08 (study day 39); relationship: not assessed

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-12-02 (study day 124); relationship: not assessed

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-12-19 (study day 141); relationship: N

severe serious assessed

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-09 (study day 221); relationship: N; serious criteria: life-threatening

moderate assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-04-01 (study day 244); relationship: not assessed

Data queries

No data queries.